百奥泰维拉西塔单抗注射液上市许可申请获得受理

Core Viewpoint - The company Baiotai (688177) has received the acceptance notice from the National Medical Products Administration for its investigational drug BAT5906, a recombinant humanized monoclonal antibody [1] Group 1: Drug Information - BAT5906 is an innovative drug developed and produced by the company, classified as an IgG1 full-length antibody with a molecular weight of 149KDa [1] - The drug specifically binds to human VEGF-A165, inhibiting neovascularization [1] - In vitro models of angiogenesis show that BAT5906 can block the binding of VEGF to its corresponding receptors, suppressing endothelial cell proliferation and new blood vessel formation [1]